Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Alphamab Oncology ( (HK:9966) ).
Alphamab Oncology announced that its drug JSKN003 has received breakthrough therapy designation from China’s National Medical Products Administration for treating certain types of cancer, including platinum-resistant recurrent epithelial ovarian cancer. This designation is expected to expedite the drug’s clinical development and approval process, potentially benefiting more patients sooner and enhancing Alphamab’s positioning in the oncology market.
More about Alphamab Oncology
Alphamab Oncology is a leading biopharmaceutical company in China, specializing in bispecific antibodies, multifunctional protein engineering, and antibody-drug conjugates (ADCs). The company has a robust in-house pipeline for oncology treatments, including monoclonal antibodies, bispecific antibodies, and ADCs, with one product approved for marketing and others in late clinical stages.
YTD Price Performance: 58.29%
Average Trading Volume: 4,729,304
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$5.35B
Find detailed analytics on 9966 stock on TipRanks’ Stock Analysis page.